At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Soticlestatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder (ARCADE Study)
In Brief
A Phase 2 clinical trial evaluating Soticlestat for 15q Duplication Syndrome and CDKL5 Deficiency Disease. Completed, enrolled 20 participants across 8 sites.
Detailed Summary
The purpose of this study is to investigate the effect of soticlestat on the frequency of motor seizures for participants with Dup15q or CDD during the Maintenance Period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Conditions15q Duplication Syndrome, CDKL5 Deficiency Disease
CountriesUnited States
CollaboratorsHealx AI
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartSep 2018
First PostedOct 2018
Primary CompletionJul 2020
Study CompletionJul 2020
TodayJul 2026
First PostedOct 3, 2018
Enrollment StartSep 10, 2018
Primary CompletionJul 13, 2020
Study CompletionJul 31, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.7 years ago
Interventions
Soticlestatdrug
TAK-935 tablets